for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Eagle Pharmaceuticals says FDA rejects company's blood thinner

March 18 (Reuters) - Eagle Pharmaceuticals Inc :

* Eagle Pharmaceuticals receives complete response letter from FDA on Kangio (RTU Bivalirudin) application

* Says FDA requested further characterization of Bivalirudin related substances in drug product

* Eagle Pharmaceuticals Inc says Eagle will work directly with FDA to determine an appropriate path forward

* Eagle Pharmaceuticals Inc says evaluating FDA’s response Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up